Psilera, a Tampa-based biotech company, has taken a significant step in advancing treatments for dementia with its psilocybin-based drug, PSIL-006. Unlike traditional psychedelics, this pharmaceutical version of psilocybin is designed to avoid inducing the hallucinogenic effects commonly associated with 'magic' mushrooms, paving the way for more accessible therapies..

位于坦帕的生物技术公司普西莱拉（Psilera）已通过其基于裸盖菇素的药物PSIL-006在推进痴呆症治疗方面迈出了重要一步。与传统的迷幻药不同，这种药物版本的裸盖菇素旨在避免诱发通常与“神奇”蘑菇相关的幻觉效应，为更容易获得的疗法铺平道路。。

The company recently announced that PSIL-006 had successfully cleared a key safety milestone in preclinical studies, demonstrating a 'strong' safety profile. This progress marks an important step toward future human trials and, potentially, FDA approval. If successful, the drug could address frontotemporal dementia (FTD), a condition that affects nearly 60 million Americans and currently lacks any FDA-approved treatments..

该公司最近宣布，PSIL-006已成功清除了临床前研究中的一个关键安全里程碑，显示出“强大”的安全性。这一进展标志着朝着未来的人体试验以及潜在的FDA批准迈出了重要的一步。如果成功，该药物可以解决额颞叶痴呆（FTD），这种疾病影响近6000万美国人，目前缺乏FDA批准的治疗方法。。

Read Also: ‘Psychedelics Are Here To Stay And They Belong To Everyone,’ Says Mycopreneur’s Dennis Walker

读读：“迷幻药会一直存在，它们属于每个人，”Mycopreneur的丹尼斯·沃克（DennisWalker）说

Advancing Dementia Treatment Without Psychedelic Effects

推进痴呆治疗而不产生迷幻作用

Psilera's PSIL-006 was tested in models that mimic FTD, showing promising improvements in memory, sleep, and learning. However, further research and rigorous clinical trials, including human testing, will be needed before the drug can be considered for FDA approval.

Psilera的PSIL-006在模拟FTD的模型中进行了测试，显示出在记忆，睡眠和学习方面的有希望的改善。然而，在考虑该药物获得FDA批准之前，还需要进一步的研究和严格的临床试验，包括人体试验。

What makes PSIL-006 unique in the field of psychedelic-based treatments is its trip-free design. Traditional psychedelics like MDMA, LSD, and psilocybin have been challenging to study in double-blind placebo trials due to their powerful effects, which make it obvious to both patients and researchers whether they have received the real drug or a placebo.

PSIL-006在迷幻药治疗领域的独特之处在于它的免旅行设计。传统的迷幻药如MDMA、LSD和psilocybin由于其强大的作用，一直难以在双盲安慰剂试验中进行研究，这使患者和研究人员都清楚他们是否服用了真正的药物或安慰剂。

This limitation has long hindered their progression through the clinical approval process..

这种限制长期以来阻碍了他们在临床批准过程中的进展。。

Because PSIL-006 lacks the typical 'trip' or any psychoactive effects of psilocybin, it may allow for more reliable double-blind trials, an essential element for achieving FDA approval. The drug is designed to deliver the therapeutic benefits of psilocybin without the mind-altering experiences, making it safer and more practical for patients with mental health sensitivities or dementia, who could otherwise experience confusion or anxiety during a psychedelic trip..

由于PSIL-006缺乏psilocybin的典型“trip”或任何精神活性作用，因此它可能允许更可靠的双盲试验，这是获得FDA批准的一个重要因素。该药物旨在提供psilocybin的治疗益处，而不会改变思维体验，使其对精神健康敏感或痴呆症患者更安全，更实用，否则他们可能会在迷幻旅行中出现困惑或焦虑。。

A New Frontier In Psychedelic Medicine

迷幻医学的新前沿

As Double Blind reported, the development of non-psychedelic versions of drugs like psilocybin is gaining momentum. Other companies, such as Boston-based Onsero Therapeutics and Delix Therapeutics are also working on trip-free psychedelic-based drugs. These compounds target the 5-HT2A receptor, the same receptor affected by psychedelics, without triggering hallucinations.

据双盲报道，裸盖菇素等非迷幻药物的开发势头正在增强。其他公司，如总部位于波士顿的Onsero Therapeutics和Delix Therapeutics，也在开发无旅行迷幻药。这些化合物靶向5-HT2A受体，即受迷幻剂影响的同一受体，而不会引发幻觉。

As Aaron Koenig, chief medical officer at Delix Therapeutics, explained to Scientific American, 'Some patients are terrified when they go through these trips, and it's not something they ever want to do again.'.

正如Delix Therapeutics首席医疗官亚伦·柯尼格（AaronKoenig）向《科学美国人》（Scientific American）解释的那样，“一些患者在经历这些旅行时会感到恐惧，他们再也不想这样做了。”。

Creating trip-free versions of these drugs offers additional benefits, including the possibility of self-administration at home rather than under clinical supervision. This could make treatment more accessible and convenient, particularly for long-term or chronic conditions like dementia.

创建这些药物的免旅行版本提供了额外的好处，包括在家中而不是在临床监督下自我管理的可能性。这可以使治疗更加容易和方便，特别是对于痴呆症等长期或慢性疾病。

The Future Of Non-Psychedelic Therapies

非迷幻疗法的未来

While the therapeutic potential of psychedelic drugs is well-documented, the focus on developing non-psychedelic derivatives has opened new avenues for treatment. These innovations are being closely watched in a multi-billion-dollar industry driven by growing demand for mental health therapies. As clinical trials progress, PSIL-006 and other non-psychedelic therapies could significantly impact the future of mental health and dementia care, addressing a critical need in the U.S., where around 60 million people are affected by mental health issues..

虽然迷幻剂药物的治疗潜力已被充分证明，但对开发非迷幻剂衍生物的关注为治疗开辟了新途径。由于对心理健康疗法的需求不断增长，这些创新在一个数十亿美元的行业中受到密切关注。随着临床试验的进展，PSIL-006和其他非迷幻剂疗法可能会对心理健康和痴呆症护理的未来产生重大影响，从而解决美国的关键需求，美国约有6000万人受到心理健康问题的影响。。

Cover image made with AiMarket News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

封面图片由AiMarket新闻和Benzinga API提供给您的数据制作©2024 Benzinga.com。Benzinga不提供投资建议。保留所有权利。